$SILK
Silk Road Medical Inc

2022 Q4 Form 10-Q Financial Statement

#000139770222000067 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $40.07M $37.37M $24.70M
YoY Change 41.77% 51.31% 23.09%
Cost Of Revenue $10.98M $9.308M $6.076M
YoY Change 51.79% 53.19% 10.71%
Gross Profit $29.09M $28.07M $18.63M
YoY Change 38.32% 50.69% 27.75%
Gross Profit Margin 72.6% 75.09% 75.4%
Selling, General & Admin $32.52M $28.82M $25.05M
YoY Change 17.85% 15.06% 30.45%
% of Gross Profit 111.79% 102.69% 134.49%
Research & Development $9.200M $8.471M $6.867M
YoY Change 22.68% 23.36% 45.77%
% of Gross Profit 31.62% 30.18% 36.87%
Depreciation & Amortization $662.0K $543.0K $241.0K
YoY Change 114.24% 125.31% 26.84%
% of Gross Profit 2.28% 1.93% 1.29%
Operating Expenses $41.72M $37.29M $31.92M
YoY Change 18.89% 16.84% 33.47%
Operating Profit -$12.63M -$9.226M -$13.29M
YoY Change -10.18% -30.58% 42.39%
Interest Expense $44.00K $1.714M $633.0K
YoY Change -107.11% 170.77% -47.9%
% of Operating Profit
Other Income/Expense, Net -$28.00K $4.000K -$3.000K
YoY Change 133.33% -233.33% -80.0%
Pretax Income -$12.61M -$10.32M -$13.89M
YoY Change -14.15% -25.68% 34.54%
Income Tax
% Of Pretax Income
Net Earnings -$12.61M -$10.32M -$13.89M
YoY Change -14.15% -25.68% 34.61%
Net Earnings / Revenue -31.48% -27.61% -56.21%
Basic Earnings Per Share -$0.29 -$0.40
Diluted Earnings Per Share -$0.34 -$0.29 -$399.7K
COMMON SHARES
Basic Shares Outstanding 38.12M 35.30M 34.68M
Diluted Shares Outstanding 35.30M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $213.7M $105.1M $122.8M
YoY Change 93.84% -14.37% -20.23%
Cash & Equivalents $55.36M $51.31M $105.6M
Short-Term Investments $158.3M $53.83M $17.13M
Other Short-Term Assets $3.924M $4.543M $4.662M
YoY Change 15.01% -2.55% 37.12%
Inventory $19.29M $20.29M $16.05M
Prepaid Expenses
Receivables $18.01M $17.02M $10.98M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $254.9M $147.0M $154.5M
YoY Change 77.84% -4.84% -13.08%
LONG-TERM ASSETS
Property, Plant & Equipment $9.372M $9.671M $5.132M
YoY Change 21.76% 88.45% 81.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.260M $5.731M $5.711M
YoY Change -2.05% 0.35% 90.56%
Total Long-Term Assets $14.79M $15.56M $11.08M
YoY Change 11.19% 40.47% 80.64%
TOTAL ASSETS
Total Short-Term Assets $254.9M $147.0M $154.5M
Total Long-Term Assets $14.79M $15.56M $11.08M
Total Assets $269.7M $162.5M $165.5M
YoY Change 72.19% -1.8% -9.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.523M $4.312M $4.908M
YoY Change 6.05% -12.14% 139.88%
Accrued Expenses $21.97M $19.62M $16.01M
YoY Change 10.92% 22.55% 23.09%
Deferred Revenue $253.0K $298.0K $448.0K
YoY Change 61.15% -33.48% 16.67%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.49M $23.93M $20.92M
YoY Change -6.13% 14.41% 38.96%
LONG-TERM LIABILITIES
Long-Term Debt $74.60M $74.34M $48.65M
YoY Change 66.56% 52.8% 7.73%
Other Long-Term Liabilities $6.726M $7.073M $7.781M
YoY Change 3.27% -9.1% 100.75%
Total Long-Term Liabilities $81.32M $81.41M $56.43M
YoY Change 58.53% 44.26% 15.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.49M $23.93M $20.92M
Total Long-Term Liabilities $81.32M $81.41M $56.43M
Total Liabilities $105.8M $105.3M $77.35M
YoY Change 36.73% 36.19% 20.69%
SHAREHOLDERS EQUITY
Retained Earnings -$343.7M -$331.1M -$274.0M
YoY Change 19.05% 20.83% 23.35%
Common Stock $38.00K $35.00K $35.00K
YoY Change 8.57% 0.0% 2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $163.9M $57.20M $88.18M
YoY Change
Total Liabilities & Shareholders Equity $269.7M $162.5M $165.5M
YoY Change 72.19% -1.8% -9.95%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$12.61M -$10.32M -$13.89M
YoY Change -14.15% -25.68% 34.61%
Depreciation, Depletion And Amortization $662.0K $543.0K $241.0K
YoY Change 114.24% 125.31% 26.84%
Cash From Operating Activities -$2.724M -$4.726M -$6.495M
YoY Change -76.17% -27.24% 46.95%
INVESTING ACTIVITIES
Capital Expenditures $1.567M -$389.0K -$1.132M
YoY Change -156.94% -65.64% 929.09%
Acquisitions
YoY Change
Other Investing Activities -$103.4M -$32.51M $9.100M
YoY Change -708.07% -457.21% -225.17%
Cash From Investing Activities -$105.0M -$32.89M $7.968M
YoY Change -836.5% -512.84% -207.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 111.7M 1.213M 2.242M
YoY Change 6208.7% -45.9% 166.9%
NET CHANGE
Cash From Operating Activities -2.724M -4.726M -6.495M
Cash From Investing Activities -105.0M -32.89M 7.968M
Cash From Financing Activities 111.7M 1.213M 2.242M
Net Change In Cash 4.052M -36.41M 3.715M
YoY Change -11.7% -1080.03% -133.9%
FREE CASH FLOW
Cash From Operating Activities -$2.724M -$4.726M -$6.495M
Capital Expenditures $1.567M -$389.0K -$1.132M
Free Cash Flow -$4.291M -$4.337M -$5.363M
YoY Change -50.56% -19.13% 24.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security12b Title
Security12bTitle
Common Stock
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Central Index Key
EntityCentralIndexKey
0001397702
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38847
dei Entity Registrant Name
EntityRegistrantName
SILK ROAD MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8777622
dei Entity Address Address Line1
EntityAddressAddressLine1
1213 Innsbruck Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94089
dei City Area Code
CityAreaCode
408
dei Local Phone Number
LocalPhoneNumber
720-9002
dei Trading Symbol
TradingSymbol
SILK
CY2021Q4 us-gaap Inventory Net
InventoryNet
17851000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4543000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3412000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
146987000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
143326000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38122549
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51306000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110231000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
53826000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17019000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11832000
CY2022Q3 us-gaap Inventory Net
InventoryNet
20293000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9671000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7697000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
155000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
232000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5731000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5370000
CY2022Q3 us-gaap Assets
Assets
162544000
CY2021Q4 us-gaap Assets
Assets
156625000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4312000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2379000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19621000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19802000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
3905000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23933000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26086000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
74340000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
44786000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7073000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6513000
CY2022Q3 us-gaap Liabilities
Liabilities
105346000
CY2021Q4 us-gaap Liabilities
Liabilities
77385000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
168000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35381085
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35381085
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34980896
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34980896
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
35000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
388452000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
367907000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-191000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-331098000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288702000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
57198000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
79240000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162544000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
156625000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37374000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24701000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
98567000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73210000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9308000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6076000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26897000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18213000
CY2022Q3 us-gaap Gross Profit
GrossProfit
28066000
CY2021Q3 us-gaap Gross Profit
GrossProfit
18625000
us-gaap Gross Profit
GrossProfit
71670000
us-gaap Gross Profit
GrossProfit
54997000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8471000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6867000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27249000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19611000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28821000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25049000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
83795000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
68792000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
37292000
us-gaap Interest Expense
InterestExpense
1884000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-245000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-162000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10319000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13885000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
4978000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-16679000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
31916000
us-gaap Operating Expenses
OperatingExpenses
111044000
us-gaap Operating Expenses
OperatingExpenses
88403000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9226000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13291000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39374000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33406000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
617000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
us-gaap Investment Income Interest
InvestmentIncomeInterest
751000
us-gaap Investment Income Interest
InvestmentIncomeInterest
183000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1714000
CY2021Q3 us-gaap Interest Expense
InterestExpense
633000
us-gaap Interest Expense
InterestExpense
3366000
us-gaap Net Income Loss
NetIncomeLoss
-42396000
us-gaap Net Income Loss
NetIncomeLoss
-35118000
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-189000
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-2000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-191000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-38000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-189000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-191000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-38000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10508000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13887000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42587000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35156000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35303958
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1031000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1086000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34736015
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35157840
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34536980
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
79240000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3409000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-10539000
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-3000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
57198000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
107500000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
848000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3533000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10694000
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-33000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
101154000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
67707000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
322000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1239000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
6161000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-15398000
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-2000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60029000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1338000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
6339000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-10319000
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-189000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
96138000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2242000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3686000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-13885000
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-2000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
88179000
us-gaap Profit Loss
ProfitLoss
-42396000
us-gaap Profit Loss
ProfitLoss
-35118000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
1465000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
723000
us-gaap Share Based Compensation
ShareBasedCompensation
17478000
us-gaap Share Based Compensation
ShareBasedCompensation
10628000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
338000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-451000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
160000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
119000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
766000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
627000
silk Paid In Kind Interest Benefit
PaidInKindInterestBenefit
823000
silk Paid In Kind Interest Benefit
PaidInKindInterestBenefit
193000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-245000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3438000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2006000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
53679000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-175000
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
60400000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57117000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-3000
us-gaap Inventory Write Down
InventoryWriteDown
5000
us-gaap Inventory Write Down
InventoryWriteDown
56000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5184000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1906000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2446000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3744000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1132000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2014000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
52000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
107000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1665000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1304000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-744000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
629000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-344000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
656000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29857000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27503000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58394000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3067000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5207000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
75000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
49000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1086000
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
9000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27972000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5207000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-59002000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36098000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110463000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69776000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51461000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105874000
us-gaap Interest Paid Net
InterestPaidNet
2383000
us-gaap Interest Paid Net
InterestPaidNet
1571000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
176000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1298000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
903000
CY2022Q3 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
785000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3398000
silk Unpaid Debt Issuance Costs
UnpaidDebtIssuanceCosts
3000
silk Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
162000
us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Due to the coronavirus, or COVID-19, pandemic, there has been continued uncertainty and disruption in the global economy, supply chain, financial markets and labor markets. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">New virus variants and varying infection rates continue to make the current COVID-related environment highly volatile and uncertain. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These challenges continued to impact the number of TCAR procedures in the first half of 2022, with </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">procedure volumes impacted </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">by increased COVID-19 hospitalizations and hospital capacity and staffing constraints due to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">COVID-19 and its variants</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of September 30, 2022. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span>
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
155000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
232000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Concentration of Credit Risk, and Other Risks and Uncertainties</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company’s operations, its revenue and overall financial condition by significantly decreasing the expected number of TCAR procedures performed. The total number of TCAR procedures performed, similar to other surgical procedures, has been significantly depressed during certain periods of time as health care organizations globally prioritized the treatment of patients with COVID-19 and managed through capacity and staffing issues. In the past governmental or hospital authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients and certain staff to COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and may continue to negatively impact the Company’s revenue while the pandemic continues. New virus variants, and varying infection rates continue to make the current COVID-related environment highly volatile and uncertain.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three and nine months ended September 30, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company’s accounts receivable are due from a variety of hospitals and medical centers in the United States. At September 30, 2022 and December 31, 2021, no customer represented 10% or more of the Company’s accounts receivable. For the three and nine months ended September 30, 2022 and 2021, there were no customers that represented 10% or more of revenue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Existing or future devices developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">currently approved portfolio. If clearance for the products in the current portfolio </span><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">were withdrawn by the FDA, this would have a material adverse impact on the Company.</span>
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
170000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
us-gaap Net Income Loss
NetIncomeLoss
-35118000
CY2022Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
229000
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
87000
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10319000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13885000
us-gaap Net Income Loss
NetIncomeLoss
-42396000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35303958
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34736015
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35157840
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34536980
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2021Q4 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
590000
CY2022Q3 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
38000
CY2021Q4 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
99000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5171338
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4280389
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
105474000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
191000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105283000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105283000
CY2022Q3 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P180D
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
731000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
665000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
298000
CY2022Q3 us-gaap Inventory Net
InventoryNet
20293000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
157000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
39050000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
191000
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
4178000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2447000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
16126000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
15437000
CY2022Q3 us-gaap Inventory Gross
InventoryGross
20304000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
17884000
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
11000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
33000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17851000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
12865000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
13898000
CY2022Q3 silk Provisions For Sales Returns
ProvisionsForSalesReturns
531000
CY2021Q4 silk Provisions For Sales Returns
ProvisionsForSalesReturns
359000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1144000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2039000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1814000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1294000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
504000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
14000
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
911000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
687000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3307000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19621000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19802000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1437000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5703000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5719000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5703000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
45699000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
34517000
CY2022Q3 silk Long Term Debt Gross Before Accretion Of Closing Fees
LongTermDebtGrossBeforeAccretionOfClosingFees
98778000
CY2022Q3 silk Accretion Of Closing Costs
AccretionOfClosingCosts
333000
CY2022Q3 silk Long Term Debt Gross After Accretion Of Closing Fees
LongTermDebtGrossAfterAccretionOfClosingFees
99111000
CY2022Q3 silk Long Term Debt Unpaid Interest
LongTermDebtUnpaidInterest
23779000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
992000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
74340000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3307000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
408000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
369000
us-gaap Operating Lease Cost
OperatingLeaseCost
1151000
us-gaap Operating Lease Cost
OperatingLeaseCost
875000
CY2022Q3 silk Operating Lease Cash Paid
OperatingLeaseCashPaid
310000
CY2021Q3 silk Operating Lease Cash Paid
OperatingLeaseCashPaid
-1043000
silk Operating Lease Cash Paid
OperatingLeaseCashPaid
-248000
silk Operating Lease Cash Paid
OperatingLeaseCashPaid
-650000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0656
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M23D
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5356000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5219000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1814000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1294000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6378000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5747000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8192000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7041000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
483000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1967000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1764000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1079000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1173000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3593000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10059000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1867000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8192000
CY2022Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
16645000
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2022Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
93818000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35381085
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021 silk Stockholder Short Swing Profits
StockholderShortSwingProfits
32000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3780939
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.45
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M15D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
91900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
566862
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
37.37
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
253318
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
70965
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
40.60
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4023518
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2951426
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M10D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
84891000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4023518
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
23.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
93818000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6339000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3686000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17478000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10628000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18882000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M15D
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.90
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2022Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
352000
CY2021Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
308000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1394000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1003000
CY2022Q4 silk Number Of Additional Shares Purchase
NumberOfAdditionalSharesPurchase
348837

Files In Submission

Name View Source Status
silk-20220930x10q_htm.xml Edgar Link completed
0001397702-22-000067-index-headers.html Edgar Link pending
0001397702-22-000067-index.html Edgar Link pending
0001397702-22-000067.txt Edgar Link pending
0001397702-22-000067-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
silk-20220930.xsd Edgar Link pending
silk-20220930x10q.htm Edgar Link pending
silk-20220930xex10_1.htm Edgar Link pending
silk-20220930xex31_1.htm Edgar Link pending
silk-20220930xex31_2.htm Edgar Link pending
silk-20220930xex32_1.htm Edgar Link pending
silk-20220930_cal.xml Edgar Link unprocessable
silk-20220930_def.xml Edgar Link unprocessable
silk-20220930_lab.xml Edgar Link unprocessable
silk-20220930_pre.xml Edgar Link unprocessable